Paraoxonase1 55 and 192 Gene Polymorphisms in an Egyptian Population with Diabetic Complications

Mohamed Abdel-Halem Helaly 1 * , Ehab El-Said Abdel-Khalek 1, Hala A. Abdel-Hafez 1, Eman Fathi Ibrahem 2, Ahmed Wafa Soliman 3, Eid Mohamed Daoud 3, Zakaria Fawzy Lotfy 4
More Detail
1 Mansoura University, Department of Internal Medicine
2 Cairo University Department of Internal Medicine
3 Mansoura University, Department of Cardiology
4 Mansoura University, Department of Clinical Pathology
* Corresponding Author
EUR J BASIC MED SCI, Volume 3, Issue 1, pp. 9-16.
Download Full Text (PDF)


Type 2 diabetes mellitus is the most common type of diabetes worldwide with serious macro- and microvascular complications. It is a polygenic disease characterized by interaction of environmental and genetic factors. The paraoxonase 1 gene (PON1) 55 and 192 polymorphisms have been reported to be associated with type 2 diabetes and its complications. Our aim is to study the PON1 55 , 192 gene polymorphisms and enzyme activity in type 2 diabetic Egyptian population with complications. 100 type 2 diabetic patients with complications (34 with cardiac and 66 with microvascular complications (neuropathy, retinopathy and/or nephropathy). This was in addition to 100 healthy control subjects of matched age and sex were taken. PON1 55 L⁄M and 192 Q⁄R gene polymorphisms and PON1 enzyme activity serum levels were detected. The LL genotype of PON1 55 polymorphism and QR and QQ genotypes of PON1 192 polymorphism were more frequent among the patients with diabetic complications. The PON1 enzyme activity levels were lower among the diabetic patients than in control subjects. PON1 55 and 192 polymorphisms and enzyme activity seems to be related to diabetic complications in an Egyptian type 2 diabetic patients.


Helaly MAH, Abdel-Khalek EES, Abdel-Hafez HA, Ibrahem EF, Soliman AW, Daoud EM, et al. Paraoxonase1 55 and 192 Gene Polymorphisms in an Egyptian Population with Diabetic Complications. Eur J Basic Med Sci. 2013;3(1):9-16.


  • Groop LC. The molecular genetics of non-insulin-dependent diabetes mellitus. J Intern Med 1997; 241: 95–101.
  • Potluri R, Purmah Y, Dowlut M, Sewpaul N, Lavu D. Microvascular diabetic complications are more prevalent in India compared to Mauritius and the UK due to poorer diabetic control. Diabetes Res Clin Pract 2009; 86: 39–40.
  • Mackness B, Durrngton PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr.Opin. Lipidol 2002; 13: 357-62.
  • Mackness B, Mackness MI, Arrol S, Turkei W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphism on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.
  • Senti M, Tomas M, Marrugat J, Elosua R. Paraoxonase 1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol 2001; 21: 415.
  • Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33: 498–507.
  • Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598–608.
  • Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, and Kano K. Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraoxonase 1 gene (Q192R) polymorphism? Eur.J.Endocrinol 2001; 144: 639-44.
  • Arca M, Ombres D, Montali, Campagna F, Mangieri E, Tanzilli G, et al. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002; 32: 9-15.
  • Kamei N, Yamane K, Nakanishi S, Yamashita Y, Tamura T, Ohshita K, et al. Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening. J Diabetes Complications 2005; 19 (1): 47-53.
  • Gries FA, Cameron NE, Low PA, Ziegler D. Textbook of Diabetic Neuropathy. Thieme Medical Publishers 2003.
  • Rathur HM, Boulton AJ. Recent advances in the diagnosis and management of diabetic neuropathy. J Bone Joint Surg Br 2005; 87 (12): 1605-10.
  • American Diabetes Association: Diabetic retinopathy. Diabetes care 2001; 24 (supl.1): S73-6.
  • Biesenbach G, Bodlaj G, Pierninger H, Sedlak M. Clinical versus histological diagnosis of diabetic nephropathy- is renal biopsy required in type 2 diabetic patients with renal disease? QJM 2011; 104 (9): 771-4.
  • KDIGO GN Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney inter., Suppl 2012; 2: 139–274.
  • Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyriphos oxon and paraoxon. Am J Human Genet 1988; 43: 230–8.
  • Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999; 56: 289-98.
  • Ueno T, Shimazaki E, Matsumoto T, Watanabe H, Tsunemi A, Takahashi Y, et al. Paraoxonase1 polymorphism Leu- Met55 is associated with cerebral infarction in Japanese population. Med Sci Monit 2003; 9: CR208–12.
  • Hu Y, Tian H, Liu R. Gln-Arg192 polymorphism of paraoxonase 1 is associated with carotid intima-media thickness in patients of type 2 diabetes mellitus of Chinese. Diabetes Res Clin Pract 2003; 61: 21–7.
  • Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17: 3565–9.
  • Kotani K, Tsuzaki K, Sakane N. Paraoxonase-1 Gene Q192R Polymorphism and Reactive Oxygen Metabolites. J Int Med Res 2012; 40(4):1513-8.
  • Mackness B, Marsillach J, Elkeles RS, Godsland IF, Feher MD, Rubens MB, et al. Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: Results from the PREDICT study. Dis Markers 2012; 33(2):101-12.
  • Demirdogen BC, Demirkaya S, Tu¨rkanoglu A, Bek S, Arinc E, Adali O. Analysis of paraoxonase 1 (PON1) genetic polymorphisms and activities as risk factors for ischemic stroke in Turkish population. Cell Biochem Funct 2009; 27: 558–67.
  • Kaman D, Ilhan N, Metin K, Akbulut M, Ustundag B. A preliminary study of human paraoxonase and PON 1 L/M55- PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease. Cell Biochem Funct 2009; 27: 88–92.
  • Aynacioglu AS, Kepekci Y. The human paraoxonase Gln-Argl92 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol 2000; 74: 33–7.
  • Ozkok E, Aydin M, Babalik E, Ozbek Z, Ince N, Kara I. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med Sci Monit 2008; 14(10): CR536–42.
  • Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010; 61: 157–65.
  • Agrawal S, Tripathi G, Prajnya R, Sinha N, Gilmour A, Bush L, et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J Med Sci 2009; 63: 335–44.
  • Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) 2000; 98: 355–63.
  • Kao YL, Donaghue K, Chan A, Knight J, Silink M. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 1998; 83: 2589–92.
  • Bilge I, Sirin A, Agachan B, Emre S, Sadikoglu B, Yilmaz H, et al. Is paraoxonase 192 gene polymorphism a risk factor for membranoproliferative glomerulonephritis in children? Cell Biochem Funct 2007; 25: 159–65.
  • Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 2004; 53: 297–302.
  • Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity,concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812–8.
  • Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 1711–6.
  • Ergun M, Yurtcu E , Demirci H , Ilhan M , Barkar V, Yetkin I , et al: PON1 55 and 192 Gene Polymorphisms in Type 2 Diabetes Mellitus Patients in a Turkish Population. Biochem Genet 2011; 49(1-2):1-8.